Stocks to watch: Tata Power, Reliance Infra, Arvind Mills, Sundaram Finance
Tata Power and Reliance Infrastructure have been locked in an escalating and bitter war of words over the terms of supply of power to Mumbai’s suburbs.
By ET Bureau |
Tata Power and Reliance Infrastructure have been locked in an escalating and bitter war of words over the terms of supply of power to Mumbai’s suburbs. Both companies have approached the state government and the regulator, Maharashtra Electricity Regulatory Commission with proposals to take over the power generation and distribution assets of the other.
Arvind Brands is close to a deal to bring Italian menswear label Energie to the country, ending its three-year long wait to retail an international denim brand. The Rs 230-crore subsidiary of Arvind Mills, which retails internationals brands such as Arrow and Izod, has been in talks with Italian fashion firm Sixty Group that owns Energie for at least four months.
Chennai-based Sundaram Finance Group is set to buy French bank BNP Paribas’ 49.90% stake in their domestic mutual fund joint venture, Sundaram BNP Paribas Asset Management.
Glenmark Pharmaceuticals has gained the upper hand in a legal battle against Merck over a cholesterol control pill after a US court rejected most of the American drug company’s patent claims. A New Jersey District court rejected 10 of the 13 patent claims after Glenmark challenged Merck’s patent so that it can launch a generic version of Ezetimibe by around November.
Results diary: ACC, Ambuja Cements, EscortsRallis, Indiabulls Power, Strides Arcolab, Coromandel, Gujarat Gas
Arvind Brands is close to a deal to bring Italian menswear label Energie to the country, ending its three-year long wait to retail an international denim brand. The Rs 230-crore subsidiary of Arvind Mills, which retails internationals brands such as Arrow and Izod, has been in talks with Italian fashion firm Sixty Group that owns Energie for at least four months.
Chennai-based Sundaram Finance Group is set to buy French bank BNP Paribas’ 49.90% stake in their domestic mutual fund joint venture, Sundaram BNP Paribas Asset Management.
Glenmark Pharmaceuticals has gained the upper hand in a legal battle against Merck over a cholesterol control pill after a US court rejected most of the American drug company’s patent claims. A New Jersey District court rejected 10 of the 13 patent claims after Glenmark challenged Merck’s patent so that it can launch a generic version of Ezetimibe by around November.
Results diary: ACC, Ambuja Cements, EscortsRallis, Indiabulls Power, Strides Arcolab, Coromandel, Gujarat Gas
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
Water crisis ahead? PL Capital says water deficit creates Rs 20 lakh cr infra opportunity, picks 3 stocks2026-06-30T08:37:42Z- US stocks may be headed for a sharp correction, warns Andrew Freris amid AI spending boom2026-06-30T06:45:03Z
- PFC-REC merger: Which stock should you buy before the mega deal creates Rs 11 lakh cr power financing giant2026-06-30T04:51:17Z
ADVERTISEMENT
